Petrelintide trial shows 10% weight loss with low GI side effects
Nausea hit 20% of petrelintide users versus 6% on placebo, and only 1.5% stopped the drug for gastrointestinal adverse events.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 5 06:00 ETSource: Drugs.com
The wire
- 01In a 485-person trial across 32 sites in Poland, Romania and the US, weekly petrelintide at 1 to 9 mg produced 8.7% to 10.5% weight loss over 42 weeks versus placebo.
- 02The amylin analog delivered less weight loss than typical GLP-1 results but with far fewer treatment-limiting gastrointestinal effects, a tolerability trade-off clinicians may weigh for patients seeking double-digit loss.
- 03Findings were presented at EASD in Milan and published in The Lancet Diabetes and Endocrinology; the trial was funded by Zealand Pharma, and confirmatory phase 3 data are still pending.
From the source
Read at drugs.comNew Class Of Weight-Loss Drugs May Have Fewer Side Effects Than GLP-1s
MONDAY, Oct. 5, 2026 — An emerging class of weight-loss medications helps users shed pounds but with a much lower risk for gastrointestinal side effects compared to popular GLP-1s, researchers report.The weekly injected medications are called...
